1-24 of 70 Books

Competition in the pharmaceutical industry
By Meir Statman
"Man-in-the-plant" revisited, a deceptive drug labeling practice continues
"Man-in-the-plant" revisited, a deceptive drug labeling practice continues
By United States. Congress. House. Committee on Interstate and Foreign Commerce. Subcommittee on Oversight and Investigations.
Greater access to generic drugs
Greater access to generic drugs
By Michelle Meadows
FDA ensures equivalence of generic drugs
FDA ensures equivalence of generic drugs
By Jeffrey Yorke
Increasing generic drug utilization
Increasing generic drug utilization
By United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health

Generic drug entry prior to patent expiration
By United States. Federal Trade Commission.
Generic substitution and prescription drug prices
Generic substitution and prescription drug prices
By Alison Masson

Drug comparison handbook
By Reilly, Robert Pharm.D.
The future of generic drugs in Ireland
The future of generic drugs in Ireland
By Murphy, Michael.

Mosby's Drug Consult 2006 (Mosby's Drug Consult)
By Mosby
The market for Rx-to-OTC switches (A Kalorama Information market intelligence report)
The market for Rx-to-OTC switches (A Kalorama Information market intelligence report)
By Melissa Hutchison

The consumer's guide to generic drugs
By Donald L. Sullivan
Pricing, patent loss and the market for pharmaceuticals
Pricing, patent loss and the market for pharmaceuticals
By Richard G. Frank

Generic drug enforcement
By United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health and the Environment.
The Market for RX-To-OTC Switches (Kalorama Information Market Intelligence Report)
The Market for RX-To-OTC Switches (Kalorama Information Market Intelligence Report)
By Melissa Elder

Drug pricing
By United States. Congress. Senate. Committee on Governmental Affairs.
The market for prescription generic drugs (A Kalorama Information market intelligence report)
The market for prescription generic drugs (A Kalorama Information market intelligence report)
By Mary Anne Crandall
Programs to control prescription drug costs under Medicaid and Medicare could be strengthened
Programs to control prescription drug costs under Medicaid and Medicare could be strengthened
By United States. General Accounting Office